Yeungnam University College of Pharmacy Professor Jongo Kim Selected for Ministry of Science and ICT "Global Leader Research" Program

Yeungnam University (President Choi Oechul) announced on June 5 that Professor Jongo Kim of the College of Pharmacy has been selected for the Ministry of Science and ICT's 2025 Basic Research Project, "Global Leader Research." The "Global Leader Research" project is designed to identify top-tier scientists in Korea with world-class research capabilities and provide them with substantial, long-term research funding. This year, out of a total of 94 applicants, only six, including Professor Kim, were ultimately selected.

With this selection, Professor Jongo Kim will receive up to 7 billion KRW in research funding over a maximum of nine years (evaluated in three phases of three years each), starting in June. The Ministry of Science and ICT plans to support the six selected leader researchers after conducting an in-depth evaluation of the creativity and challenge of their research, as well as the researchers' capabilities.

Professor Jongo Kim, College of Pharmacy, Yeungnam University

Professor Kim's research project is titled "Development of RNA Nanovaccines Mimicking Antibiotic-Resistant Bacteria." This research aims to address the problem of super bacteria that are resistant to antibiotics by developing RNA-based vaccine technology that mimics bacterial structures, thereby maximizing immune responses and creating a next-generation vaccine platform that targets both prevention and treatment.

In particular, RNA vaccines using nanotechnology-based delivery systems are more efficient than conventional vaccines and are gaining attention as a core technology for responding to infectious diseases. Professor Kim's research is expected to accelerate the commercialization of high-performance vaccines and make a significant contribution to strengthening preventive healthcare infrastructure.

Professor Kim stated, "Through this research, I hope to present new solutions for responding to infectious diseases and contribute to enhancing the global competitiveness of vaccine technology."

This content was produced with the assistance of AI translation services.